Yahoo
Paris - Delayed Quote EUR

ABIONYX Pharma SA (ABNX.PA)

1.5680 -0.0480 (-2.97%)
At close: 5:35:13 PM GMT+1
View in AlphaSpace Currency in EUR All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
3,877
4,063
4,551
4,640
5,252
Cost of Revenue
3,468
3,529
3,707
4,022
4,616
Gross Profit
409
534
844
618
636
Operating Expense
5,766
5,962
5,167
3,783
4,612
Operating Income
-5,357
-5,428
-4,323
-3,165
-3,976
Net Non Operating Interest Income Expense
-2,532
-47
111
-66
-136
Pretax Income
-8,056
-5,541
-4,381
-3,518
-4,206
Tax Provision
2
9
0
0
0
Net Income Common Stockholders
-8,058
-5,550
-4,381
-3,518
-4,206
Diluted NI Available to Com Stockholders
-8,058
-5,550
-4,381
-3,518
-4,206
Basic EPS
-0.22
-0.16
-0.13
-0.11
-0.15
Diluted EPS
-0.22
-0.16
-0.13
-0.11
-0.15
Basic Average Shares
36,023.3260
35,491.0250
35,152.2700
32,686.8880
28,397.2750
Diluted Average Shares
40,705.3250
38,895.7840
35,152.2700
32,686.8880
30,319.1920
Total Operating Income as Reported
-5,478
-5,538
-4,465
-3,412
-4,109
Total Expenses
9,234
9,491
8,874
7,805
9,228
Net Income from Continuing & Discontinued Operation
-8,058
-5,550
-4,381
-3,518
-4,206
Normalized Income
-7,967.2500
-5,440
-4,239
-3,271
-4,073
Interest Income
82
54
104
60
6
Interest Expense
1,688
85
37
19
61
Net Interest Income
-2,532
-47
111
-66
-136
EBIT
-6,368
-5,456
-4,344
-3,499
-4,145
EBITDA
-6,168
-5,298
-4,209
-3,346
-4,010
Reconciled Cost of Revenue
3,468
3,529
3,707
4,022
4,616
Reconciled Depreciation
57
126
135
153
135
Net Income from Continuing Operation Net Minority Interest
-8,058
-5,550
-4,381
-3,518
-4,206
Total Unusual Items Excluding Goodwill
-121
-110
-142
-247
-133
Total Unusual Items
-121
-110
-142
-247
-133
Normalized EBITDA
-6,047
-5,188
-4,067
-3,099
-3,877
Tax Rate for Calcs
0.0003
0
0
0
0
Tax Effect of Unusual Items
-30.2500
0
0
0
0
12/31/2022 - 3/30/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: